
Pfizer’s ALK lung cancer drug Lorviqua lands 1st-line reimbursement in Korea
Pfizer Korea has secured reimbursement for Lorviqua (lorlatinib) as a first-line treatment for ALK-positive metastatic non-small cell lung cancer (NSCLC), a move that could expand access for younger, non-smoking patients facing high risk of brain …